Subtopic Deep Dive

Closed-System Transfer Devices
Research Guide

What is Closed-System Transfer Devices?

Closed-System Transfer Devices (CSTDs) are engineering controls designed to prevent the escape of antineoplastic drug aerosols and liquids during compounding and administration in healthcare settings.

CSTDs like PhaSeal and EquaShield maintain a closed system throughout drug transfer to minimize occupational exposure. Studies measure surface contamination levels of drugs such as cyclophosphamide before and after CSTD implementation using wipe sampling. Over 20 papers document reductions in contamination across US, European, and Japanese pharmacies.

Curated Papers

Key Challenges

Why It Matters

CSTDs reduce surface contamination by up to 90% in hospital pharmacies, protecting pharmacy staff from chronic exposure to hazardous antineoplastics (Sessink et al., 2010; Sessink et al., 2013). Mandated by USP <800> guidelines, they lower mutation rates and cancer risks in handlers (Siderov et al., 2009). Cost-effectiveness analyses support adoption despite initial expenses, with MEWIP project data showing sustained low contamination via regular monitoring (Kiffmeyer et al., 2012).

Key Research Challenges

Residual Contamination Persistence

CSTDs reduce but do not eliminate surface contamination entirely, as shown in barrier isolators (Simon et al., 2016). Wipe sampling detects trace cyclophosphamide post-implementation (Sessink et al., 2013). Long-term monitoring reveals variability across devices.

Device Usability Variability

Different CSTDs like PhaSeal and EquaShield vary in handling ease and compatibility with vials (Clark and Sessink, 2013). Training needs affect adoption rates in pharmacies (Siderov et al., 2009). Standardized usability metrics remain inconsistent.

Cost-Effectiveness Justification

High upfront costs challenge implementation despite contamination reductions (Sessink et al., 2010). Comparative studies across 22 US pharmacies highlight economic barriers (Sessink et al., 2010). ROI calculations require contamination exposure models.

Essential Papers

Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device

P.J.M. Sessink, Thomas H. Connor, James A. Jorgenson et al. · 2010 · Journal of Oncology Pharmacy Practice · 153 citations

Purpose. Surface contamination with the antineoplastic drugs cyclophosphamide, ifosfamide, and 5-fluorouracil was compared in 22 US hospital pharmacies following preparation with standard drug prep...

Application and Assessment of a Regular Environmental Monitoring of the Antineoplastic Drug Contamination Level in Pharmacies - The MEWIP Project

Thekla Kiffmeyer, Jochen Tuerk, Moritz Hahn et al. · 2012 · The Annals of Occupational Hygiene · 97 citations

A large-scale study was carried out in order to determine the contamination level of antineoplastic drugs in pharmacies and to investigate the suitability and effects of wipe sample monitoring at r...

Surface Contamination of Cyclophosphamide Packaging and Surface Contamination with Antineoplastic Drugs in a Hospital Pharmacy in Sweden

Maria Hedmer, Anastasia Georgiadi, Eva Rämme Bremberg et al. · 2005 · The Annals of Occupational Hygiene · 82 citations

Workplaces, e.g. hospital pharmacies and hospital departments, where antineoplastic drugs are handled might be contaminated with these drugs, and pharmacy personnel and health care workers may be e...

Reduction in Surface Contamination with Cyclophosphamide in 30 US Hospital Pharmacies following Implementation of a Closed-System Drug Transfer Device

P.J.M. Sessink, Jason Trahan, Joseph W. Coyne · 2013 · Hospital Pharmacy · 75 citations

Purpose In a follow-up to a previous study, surface contamination with the antineoplastic drug cyclophosphamide was compared in 30 US hospital pharmacies from 2004 to 2010 following preparation wit...

Reducing workplace cytotoxic surface contamination using a closed-system drug transfer device

Jim Siderov, Sue Kirsa, Robert McLauchlan · 2009 · Journal of Oncology Pharmacy Practice · 71 citations

Background. The potential for staff exposure to antineoplastic agents exists in the workplace despite current recommended safe handling procedures. Reliance on cytotoxic drug safety cabinets (CDSC)...

Use of a closed system drug-transfer device eliminates surface contamination with antineoplastic agents

Bernadette A Clark, P.J.M. Sessink · 2013 · Journal of Oncology Pharmacy Practice · 62 citations

Purpose To evaluate the effectiveness of a closed system drug-transfer device, EquaShield®, at reducing surface contamination with antineoplastic agents throughout an ambulatory cancer chemotherapy...

Dose Rounding of Biologic and Cytotoxic Anticancer Agents: A Position Statement of the Hematology/Oncology Pharmacy Association

Rebecca J Fahrenbruch, Polly E. Kintzel, Anne Marie Bott et al. · 2018 · Journal of Oncology Practice · 62 citations

Purpose: To present a position statement from the Hematology/Oncology Pharmacy Association (HOPA) that pertains to dose rounding of biologic and cytotoxic anticancer agents. Methods: The HOPA Stand...

Reading Guide

Foundational Papers

Start with Sessink et al. (2010, 153 citations) for PhaSeal benchmark in 22 US pharmacies, then Kiffmeyer et al. (2012, 97 citations) for MEWIP monitoring protocol, followed by Hedmer et al. (2005, 82 citations) on baseline contamination sources.

Recent Advances

Study Simon et al. (2016) for controlled CSTD trial confirming partial reductions, Clark and Sessink (2013) on EquaShield in infusion centers, Miyake et al. (2013) on Japanese cyclophosphamide exposure.

Core Methods

Wipe sampling with LC-MS/MS quantifies cyclophosphamide on surfaces; pre/post-intervention comparisons assess CSTDs; environmental monitoring tracks long-term efficacy (Sessink et al., 2010; Kiffmeyer et al., 2012).

How PapersFlow Helps You Research Closed-System Transfer Devices

Discover & Search

Research Agent uses searchPapers to find Sessink et al. (2010) on PhaSeal reductions (153 citations), then citationGraph reveals follow-ups like Sessink et al. (2013), and findSimilarPapers uncovers Kiffmeyer et al. (2012) MEWIP monitoring.

Analyze & Verify

Analysis Agent applies readPaperContent to extract wipe sampling data from Simon et al. (2016), verifies contamination stats with verifyResponse (CoVe), and runs PythonAnalysis for meta-analysis of % reductions across Sessink studies using pandas for statistical verification and GRADE grading of evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in post-2016 CSTD comparisons, flags contradictions between PhaSeal and EquaShield efficacy, then Writing Agent uses latexEditText, latexSyncCitations for Sessink papers, and latexCompile to generate reports with exportMermaid flowcharts of contamination pathways.

Use Cases

"Compare cyclophosphamide contamination reductions in Sessink 2010 vs 2013 studies"

Research Agent → searchPapers(cyclophosphamide CSTD) → Analysis Agent → readPaperContent + runPythonAnalysis(pandas plot % reductions) → statistical summary table output.

"Draft USP 800 compliant CSTD implementation report"

Synthesis Agent → gap detection → Writing Agent → latexEditText(intro) → latexSyncCitations(Sessink et al.) → latexCompile → PDF report with guidelines integration.

"Find code for modeling CSTD aerosol escape"

Research Agent → exaSearch(CSTD simulation) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → validated simulation script.

Automated Workflows

Deep Research workflow scans 50+ CSTD papers via searchPapers chains, structures contamination meta-analysis report with GRADE scores. DeepScan applies 7-step verification to Sessink et al. (2010) data, checkpointing wipe sample stats. Theorizer generates hypotheses on EquaShield vs PhaSeal from citationGraph clusters.

Try Doxa for Closed-System Transfer Devices Research

Frequently Asked Questions

What are Closed-System Transfer Devices?

CSTDs like PhaSeal prevent aerosol/liquid escape during antineoplastic compounding by maintaining closed fluid paths (Sessink et al., 2010).

What methods evaluate CSTD effectiveness?

Wipe sampling measures surface contamination of cyclophosphamide/ifosfamide pre/post-CSTD, with LC-MS detection (Kiffmeyer et al., 2012; Simon et al., 2016).

What are key papers on CSTDs?

Sessink et al. (2010, 153 citations) shows 90% contamination drop in 22 US pharmacies; Sessink et al. (2013, 75 citations) confirms in 30 pharmacies (PhaSeal).

What open problems exist in CSTD research?

Total elimination of residual contamination, device standardization, and cost-benefit models across diverse antineoplastics remain unresolved (Simon et al., 2016).